Product Information for the Patient
Scemblix 20 mg Film-Coated Tablets
Scemblix 40 mg Film-Coated Tablets
asciminib
This medicine is subject to additional monitoring, which will facilitate the detection of new information about its safety. You can contribute by reporting any adverse effects you may experience. The final part of section 4 includes information on how to report these adverse effects.
Read this leaflet carefully before starting to take this medicine, as it contains important information for you.
What is Scemblix
Scemblix contains the active ingredient asciminib, which belongs to a group of medicines called protein kinase inhibitors.
What is Scemblix used for
Scemblix is a cancer medicine, used for the treatment in adults of a type of blood cancer (chronic myeloid leukemia) called chronic phase chronic myeloid leukemia with Philadelphia chromosome positive (CML-CP Ph+). It is given to patients who have already been treated with two or more medicines for this type of leukemia called tyrosine kinase inhibitors.
How does Scemblix work
With CML Ph+, the body produces many abnormal white blood cells. Scemblix blocks the action of a protein (BCR::ABL1) that produce these abnormal white blood cells, thus stopping their uncontrolled division and growth.
If you have any questions about how this medicine works or why you have been prescribed it, ask your doctor or pharmacist.
Do not take Scemblix
Warnings and precautions
Consult your doctor or pharmacist before starting to take Scemblix if any of the following apply to you:
Inform your doctor or pharmacist if during treatment with Scemblix:
Monitoring during your treatment with Scemblix
Your doctor will regularly review your condition to check that the treatment is having the desired effect. You will have periodic tests during treatment, including blood tests. These tests control:
Children and adolescents
Do not give this medication to children or adolescents under 18 years old.
Other medications and Scemblix
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication. In particular, inform your doctor or pharmacist if you are using:
If you are already taking Scemblix, inform your doctor of any new medication that is prescribed to you.
If you are unsure whether your medication is one of the medications mentioned above, ask your doctor or pharmacist.
Scemblix with food and drinks
Do not take this medication with food. You should take it at least 2 hours after and 1 hour before any food. For more information, “When to take Scemblix” in section 3.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, consult your doctor or pharmacist before taking this medication.
Pregnancy
Scemblix may be bad for your baby. If you are a woman of childbearing age, your doctor will explain the possible risks of taking it during pregnancy and breastfeeding.
If you are a woman who can become pregnant, your doctor may do a pregnancy test if necessary before starting treatment with Scemblix.
If you become pregnant or think you may be pregnant after starting treatment with Scemblix, inform your doctor immediately.
Contraception advice for women
If you are a woman who can become pregnant, you must use an effective contraceptive method to avoid becoming pregnant during treatment with Scemblix and at least 3 days after stopping it. Ask your doctor about the most effective contraceptive methods.
Breastfeeding
We do not know if Scemblix passes into breast milk. Therefore, you must stop breastfeeding while taking it and at least 3 days after stopping it.
Driving and using machines
The influence of this medication on your ability to drive and use machines is negligible or insignificant. If after taking this medication you experience adverse effects (such as dizziness or visual disturbances) that may affect your ability to drive or use tools or machines safely, you should avoid these activities until the effect has disappeared.
Scemblix contains lactose and sodium
If your doctor has told you that you have an intolerance to certain sugars, consult with him before taking this medication.
This medication contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
How much Scemblix to take
Your doctor will tell you exactly how many tablets you should take per day and how to take them.
The recommended dose is 1 Scemblix 40 mg tablet twice a day. Take 1 tablet, and the other, approximately 12 hours later.
Your doctor may reduce your dose or temporarily or permanently stop treatment depending on how you respond to the treatment and any possible side effects.
When to take Scemblix
Take Scemblix:
If you take this medication at the same time every day, it will help you remember to take it.
How to take Scemblix
Swallow the tablets whole with a glass of water. Do not break the tablets, or crush or chew them to ensure the correct dosage.
How long to take Scemblix
Continue taking this medication for the time your doctor tells you. This is a long-term treatment, possibly for several months or years. Your doctor will regularly review your condition to check that the treatment is having the desired effect.
If you have any questions about how long you should take this medication, talk to your doctor or pharmacist.
If you take more Scemblix than you should
If you have taken more tablets than you should, or if someone has taken it accidentally, inform your doctor, or go to the doctor immediately. Show them the packaging. You may need medical attention.
If you forget to take Scemblix
If there are less than 6 hours until your next dose, skip the missed dose and take the next dose at the usual time.
If there are more than 6 hours until your next dose, take the missed dose and then take the next dose at the usual time.
If you interrupt Scemblix treatment
Do not stop taking this medication unless your doctor tells you to.
If you have any other questions about using this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Some side effects can be serious
If you experience a serious side effect, stop taking the medicine and inform your doctor immediately.
Very common(may affect more than 1 in 10 patients)
Common(may affect 1 in 10 patients)
Uncommon(may affect up to 1 in 100 patients)
Other side effects
Other side effects are listed below. If these side effects worsen, inform your doctor or pharmacist.
Very common(may affect more than 1 in 10 patients)
Common(may affect up to 1 in 10 patients)
Uncommon(may affect up to 1 in 100 patients)
Abnormal blood test results
During treatment, blood test results may be altered, providing information to your doctor about the functioning of your organs. For example:
Very common(may affect more than 1 in 10 patients)
Common(may affect up to 1 in 10 patients)
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the national notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box after EXP. The expiration date is the last day of the month indicated.
Do not store above 25 °C.
Store in the original packaging to protect it from moisture.
Do not use this medication if you observe that the packaging is damaged or shows signs of having been manipulated.
Medications should not be disposed of through drains or trash. Ask your pharmacist how to dispose of the packaging and medications that you no longer need. This will help protect the environment.
Scemblix Composition
Each film-coated tablet of 20 mg contains asciminib hydrochloride, equivalent to 20 mg of asciminib.
Each film-coated tablet of 40 mg contains asciminib hydrochloride, equivalent to 40 mg of asciminib.
20 mg and 40 mg film-coated tablets: lactose monohydrate, microcrystalline cellulose (E460i), hydroxypropyl cellulose (E463), sodium croscarmellose (E468), polyvinyl alcohol (E1203), titanium dioxide (E171), magnesium stearate, talc (E553b), colloidal silicon dioxide, lecithin (E322), xanthan gum (E415), iron oxide red (E172).
Only the 20 mg film-coated tablets: iron oxide yellow (E172). Only the 40 mg film-coated tablets: iron oxide black (E172).
See “Scemblix contains lactose and sodium” in section 2.
Appearance of the product and contents of the pack
Scemblix 20 mg film-coated tablets (tablets): biconvex, round, pale yellow tablets with bevelled edges approximately 6 mm in diameter, embossed with the company logo on one side and with “20” on the other.
Scemblix 40 mg film-coated tablets (tablets): biconvex, round, mauve tablets with bevelled edges approximately 8 mm in diameter, embossed with the company logo on one side and with “40” on the other.
Scemblix is presented in a blister pack containing 10 film-coated tablets.
It is available in the following pack sizes:
Packs containing 20 or 60 film-coated tablets.
Scemblix 40 mg film-coated tablets are also available in a multi-pack containing 180 (3 packs of 60) film-coated tablets.
Only some pack sizes may be marketed.
Marketing Authorisation Holder
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Ireland
Responsible for manufacturing
Novartis Farmacéutica, S.A.
Gran Via de les Corts Catalanes, 764
08013 Barcelona
Spain
Novartis Pharma GmbH
Roonstrasse 25
90429 Nuremberg
Germany
Novartis Pharma GmbH
Sophie-Germain-Strasse 10
90443 Nuremberg
Germany
For further information about this medicinal product, please consult the representative of the marketing authorisation holder in your country:
België/Belgique/Belgien Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 | Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16 50 |
Luxembourg/Luxemburg Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 | |
Ceská republika Novartis s.r.o. Tel: +420 225 775 111 | Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00 |
Danmark Novartis Healthcare A/S Tlf.: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: +356 2122 2872 |
Deutschland Novartis Pharma GmbH Tel: +49 911 273 0 | Nederland Novartis Pharma B.V. Tel: +31 88 04 52 111 |
Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 810 | Norge Novartis Norge AS Tlf: +47 23 05 20 00 |
Ελλáδα Novartis (Hellas) A.E.B.E. Τηλ: +30 210 281 17 12 | Österreich Novartis Pharma GmbH Tel: +43 1 86 6570 |
España Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4888 |
France Novartis Pharma S.A.S. Tél: +33 1 55 47 66 00 | Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 |
Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 220 | România Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Novartis Slovakia s.r.o. Tel: +421 2 5542 5439 |
Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133 200 |
Κ?προς Novartis Pharma Services Inc. Τηλ: +357 22 690 690 | Sverige Novartis Sverige AB Tel: +46 8 732 32 00 |
Latvija SIA Novartis Baltics Tel: +371 67 887 070 | United Kingdom (Northern Ireland) Novartis Ireland Limited Tel: +44 1276 698370 |
Last update of the summary of product characteristics:
Other sources of information
The detailed information on this medicinal product is available on the website of the European Medicines Agency:https://www.ema.europa.eu
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.